A Retrospective Study Analyzing Cinical Outcomes after Neoadjuvant Tislelizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC
Latest Information Update: 15 Sep 2022
At a glance
- Drugs Tislelizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 15 Sep 2022 New trial record
- 09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer